Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -0.59% is 97% above its 5-year average of -23.51%, near the high end of its 5-year range (-83.29%–11.38%).
85.93% above its 12-month average of -4.19%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.97%.
EBITDA MARGIN
-0.59%
EBITDA MARGIN AVG TTM
-4.19%
EBITDA MARGIN AVG 3Y
0.10%
EBITDA MARGIN AVG 5Y
-23.51%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+85.93%
CURRENT VS 3Y AVG
-710.17%
CURRENT VS 5Y AVG
+97.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Castle Biosciences, Inc.
Market Cap
$1.04B
EBITDA Margin
-0.59%
TTM Avg
-4.19%
3Y Avg
0.10%
5Y Avg
-23.51%
Market Cap
$1.04B
EBITDA Margin
-351.42%
TTM Avg
-184.18%
3Y Avg
-130.50%
5Y Avg
-161.84%
Market Cap
$1.03B
EBITDA Margin
13.41%
TTM Avg
11.95%
3Y Avg
15.57%
5Y Avg
17.13%
Market Cap
$1.05B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$1.02B
EBITDA Margin
-1556.38%
TTM Avg
-1235.25%
3Y Avg
-1029.62%
5Y Avg
-1004.15%
Market Cap
$1.02B
EBITDA Margin
8.03%
TTM Avg
9.94%
3Y Avg
10.00%
5Y Avg
10.00%
Market Cap
$1.01B
EBITDA Margin
-358.45%
TTM Avg
-358.45%
3Y Avg
-358.45%
5Y Avg
-358.45%
Market Cap
$993.25M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Castle Biosciences, Inc. (CSTL) | $1.04B | -0.59% | -4.19% | 0.10% | -23.51% |
| Immatics N.V. (IMTX)vs › | $1.04B | -351.42% | -184.18% | -130.50% | -161.84% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 13.41% | 11.95% | 15.57% | 17.13% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 3.96% | -13.21% | -146.19% | -104.68% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | -1556.38% | -1235.25% | -1029.62% | -1004.15% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 8.03% | 9.94% | 10.00% | 10.00% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | -358.45% | -358.45% | -358.45% | -358.45% |
| Vor Biopharma Inc. (VOR)vs › | $997.03M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $993.25M | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 34.04% | 32.58% | 31.87% | 26.02% |
Gross Margin
77.3%
EBITDA Margin
-0.6%
Operating Margin
-9.0%
Net Margin
-5.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 0.97% |
| 2026-03-31 | -17.30% |
| 2025-12-31 | -0.06% |
| 2025-09-30 | -3.60% |
| 2025-06-30 | -0.97% |
| 2025-03-31 | 2.09% |
| 2024-12-31 | 11.38% |
| 2024-09-30 | 10.05% |
| 2024-06-30 | 9.61% |
| 2024-03-31 | -2.92% |
| 2023-12-31 | -3.68% |
| 2023-09-30 | -10.52% |
| 2023-06-30 | -36.13% |
| 2023-03-31 | -68.11% |
| 2022-12-31 | -52.14% |
| 2022-09-30 | -50.29% |
| 2022-06-30 | -62.41% |
| 2022-03-31 | -83.29% |
| 2021-12-31 | -54.79% |
| 2021-09-30 | -45.69% |
| 2021-06-30 | -35.93% |
| 2021-03-31 | -17.76% |
| 2020-12-31 | -16.60% |
| 2020-09-30 | -24.85% |
| 2020-06-30 | -4.27% |
| 2020-03-31 | 6.47% |
| 2019-12-31 | 15.38% |
| 2019-09-30 | 30.59% |
| 2019-06-30 | 6.47% |
| 2019-03-31 | -2.77% |
| 2018-12-31 | 42.38% |
| 2018-09-30 | -74.59% |
| 2018-06-30 | -64.98% |
| 2018-03-31 | -82.14% |
